Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer
September 3rd 2021Devimistat in combination with gemcitabine and cisplatin has moved into the phase 2 portion of a phase 1b/2 trial studying the regimen as a first-line treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.
Read More
Neoadjuvant Cabozantinib/Nivolumab Leads to Improved Resection Rates in HCC
September 2nd 2021The combination of cabozantinib and nivolumab as a neoadjuvant regimen led to encouraging margin-negative resection and major pathological response rates in patients with hepatocellular carcinoma, according to results of a single-arm, phase 1b study that were published in Nature Cancer.
Read More
Pevonedistat/Azacitidine Misses EFS End Point in Frontline Higher-Risk MDS/CMML, Low-Blast AML
September 2nd 2021The combination of pevonedistat plus azacitidine as a frontline treatment for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and low-blast acute myeloid leukemia did not achieve predefined statistical significance for the primary end point of event-free survival in the phase 3 PANTHER trial.
Read More
ASTRO Guideline Provides Clarity on Radiation Use in Soft Tissue Sarcoma
August 30th 2021The American Society for Radiation Oncology released a new clinical guideline, which was also published in Practical Radiation Oncology, outlined recommendations and patient selection for optimal radiation dosing, sequencing, and treatment planning for patients with soft tissue sarcoma.
Read More
SY-5609 Under Investigation With Atezolizumab in Colorectal Cancer Subsets
August 25th 2021The highly selective and potent CDK7 inhibitor SY-5609 is being tested in combination with atezolizumab in patients with molecularly defined subsets of colorectal cancer, as one of the cohorts of the ongoing, phase 1/1b INTRINSIC trial.
Read More
Transvaginal Ultrasound Misses Mark on Screening Endometrial Cancer in Black Women
August 20th 2021The use of transvaginal ultrasonography to measure the need for diagnostic testing of endometrial cancer missed almost 5 times more endometrial cancer cases in Black women compared with those in White women.
Read More
Average Cumulative Relative Adjuvant Chemo Dose Linked With Survival in CRC
August 17th 2021Average cumulative relative dose was found to be associated with survival over average relative dose intensity in patients with colorectal cancer, highlighting that obese patients receive lower cumulative doses of adjuvant chemotherapy and therefore may be attributed to their poorer survival outcomes.
Read More
Darolutamide Crossover Leads to High PSA Response in Nonmetastatic CRPC
July 12th 2021Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.
Read More
Sequential Mitomycin/BCG Combo Shows Preliminary Safety in High-Risk NMIBC
July 10th 2021Sequential combination treatment with mytomicin chemotherapy and Bacillus Calmette-Guérin (BCG) showed comparable safety compared with BCG alone in patients with high-risk non-muscle–invasive bladder cancer.
Read More
ctDNA Positivity Linked With Inferior DFS in Stage I to IV Colorectal Cancer
July 7th 2021Longitudinal circulating tumor DNA positivity detected at 4, 12, and 24 weeks after surgery in patients with stage I to IV colorectal cancer was significantly associated with inferior disease-free survival.
Read More
FDA Approves Rylaze for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
June 30th 2021The FDA has approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as part of a chemotherapy regimen to treat pediatric and adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products.
Read More
Phase 1 CYNK-001 Trial Expands to Include Relapsed/Refractory AML Population
June 29th 2021A phase 1 study evaluating the off-the-shelf cell therapy CYNK-001 has expanded to include patients with relapsed/refractory acute myeloid leukemia after a case of conversion to minimal residual disease negativity at its highest dose level.
Read More
Cemiplimab Approved in Europe for PD-L1+ NSCLC, Basal Cell Carcinoma
June 25th 2021The European Commission has granted approval to cemiplimab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer whose tumor cells have at least 50% PD-L1 expression and no EGFR, ALK, or ROS1 aberrations and are ineligible for definitive chemoradiation.
Read More
Luspatercept Achieves Impressive Hemoglobin Increase in Non-Transfusion–Dependent Beta-Thalassemia
June 11th 2021Luspatercept-aamt achieved a 77.1% mean hemoglobin increase of 1.0 g/dL or higher from baseline over a continuous 12-week interval during weeks 13 to 24 in the absence of red blood cell transfusions vs 0% with placebo in patients with non-transfusion–dependent β-thalassemia.
Read More
Pimitespib Doubles PFS in Advanced Refractory GIST
June 8th 2021The heat shock protein 90 inhibitor pimitespib led to a significant improvement in progression-free survival and prolongation in overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib.
Read More
Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane
June 7th 2021OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.
Read More